Ethical issues in oncology biostatistics

DOI10.1191/0962280202sm301razbMath1121.62670OpenAlexW1970489508WikidataQ52944236 ScholiaQ52944236MaRDI QIDQ5424159

Peter F. Thall

Publication date: 2 November 2007

Published in: Statistical Methods in Medical Research (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1191/0962280202sm301ra

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• The two-armed bandit with delayed responses
• Investigating therapies of potentially great benefit: ECMO. With comments and a rejoinder by the author
• Ethics and statistics in randomized clinical trials. With comments and a rejoinder by the author
• Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials
• Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Coupled Error Spending Functions for Parallel Bivariate Sequential Tests
• A consistent estimator for the distribution of quality adjusted survival time
• Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• Approximate Bayesian Evaluation of Multiple Treatment Effects
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

This page was built for publication: Ethical issues in oncology biostatistics